BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20404128)

  • 1. Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
    Abed Y; Simon P; Boivin G
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2819-22. PubMed ID: 20404128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation.
    Abed Y; Pizzorno A; Boivin G
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4375-80. PubMed ID: 22664977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.
    Smee DF; Hurst BL; Wong MH; Tarbet EB; Babu YS; Klumpp K; Morrey JD
    Antiviral Res; 2010 Oct; 88(1):38-44. PubMed ID: 20633577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-influenza virus activity of peramivir in mice with single intramuscular injection.
    Bantia S; Arnold CS; Parker CD; Upshaw R; Chand P
    Antiviral Res; 2006 Jan; 69(1):39-45. PubMed ID: 16325932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice.
    Bantia S; Kellogg D; Parker C; Upshaw R; Ilyushina NA; Babu YS
    Antiviral Res; 2011 Apr; 90(1):17-21. PubMed ID: 21316393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
    Abed Y; Baz M; Boivin G
    Antivir Ther; 2006; 11(8):971-6. PubMed ID: 17302366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
    Kobayashi M; Kodama M; Noshi T; Yoshida R; Kanazu T; Nomura N; Soda K; Isoda N; Okamatsu M; Sakoda Y; Yamano Y; Sato A; Kida H
    Antiviral Res; 2017 Mar; 139():41-48. PubMed ID: 28012921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
    Onishi M; Kitano M; Taniguchi K; Homma T; Kobayashi M; Yoshinaga T; Naito A; Sato A
    Antiviral Res; 2015 May; 117():52-9. PubMed ID: 25752738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice.
    Boltz DA; Ilyushina NA; Arnold CS; Babu YS; Webster RG; Govorkova EA
    Antiviral Res; 2008 Nov; 80(2):150-7. PubMed ID: 18573280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.
    Baz M; Abed Y; Boivin G
    Antiviral Res; 2007 May; 74(2):159-62. PubMed ID: 17137644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir.
    Renaud C; Pergam SA; Polyak C; Jain R; Kuypers J; Englund JA; Corey L; Boeckh MJ
    Transpl Infect Dis; 2010 Dec; 12(6):513-7. PubMed ID: 21062390
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Lloren KKS; Kwon JJ; Choi WS; Jeong JH; Ahn SJ; Choi YK; Baek YH; Song MS
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30602610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses.
    Baz M; Abed Y; Simon P; Hamelin ME; Boivin G
    J Infect Dis; 2010 Mar; 201(5):740-5. PubMed ID: 20100088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice.
    Kitano M; Kodama M; Itoh Y; Kanazu T; Kobayashi M; Yoshida R; Sato A
    Antimicrob Agents Chemother; 2013 May; 57(5):2286-94. PubMed ID: 23478960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1).
    Yun NE; Linde NS; Zacks MA; Barr IG; Hurt AC; Smith JN; Dziuba N; Holbrook MR; Zhang L; Kilpatrick JM; Arnold CS; Paessler S
    Virology; 2008 Apr; 374(1):198-209. PubMed ID: 18234269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016.
    Takashita E; Fujisaki S; Shirakura M; Nakamura K; Kishida N; Kuwahara T; Shimazu Y; Shimomura T; Watanabe S; Odagiri T;
    Euro Surveill; 2016 Jun; 21(24):. PubMed ID: 27336226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.
    Tu V; Abed Y; Barbeau X; Carbonneau J; Fage C; Lagüe P; Boivin G
    Antiviral Res; 2017 Jan; 137():6-13. PubMed ID: 27838351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.
    Tarbet EB; Maekawa M; Furuta Y; Babu YS; Morrey JD; Smee DF
    Antiviral Res; 2012 Apr; 94(1):103-10. PubMed ID: 22429564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.